Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol in Pre-Motor and Symptomatic Parkinson's Disease
NCT04218968Phase 2Active, not recruiting
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Dec 2019
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carvedilol in Parkinson's disease (PD) and REM sleep behavior disorder (RBD), sponsored by Cedars-Sinai Medical Center. Primary endpoint: Changes in 123I-Ioflupane uptake - DATscan at 3 years. Started Dec 2019; status: active, not recruiting.
02
Drugs
carvedilol
03
Conditions
Parkinson's disease (PD)REM sleep behavior disorder (RBD)
Beyond the preview
Go deeper on NCT04218968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04218968.